Market Research Logo

Immune Checkpoint Inhibitors Market (2nd edition), 2015-2025

Immune Checkpoint Inhibitors Market (2nd edition), 2015-2025

Cancer is known to be one of the leading causes of death worldwide. The field of oncology is vast and comprises several indications, including some rare / orphan forms. Although oncology continues to be one of the most active areas in terms of drug development, there is still a significant unmet need. The focus of drug developers is gradually moving towards immunotherapeutics, which make use of the body’s own immune system or its components to fight cancer. It is a relatively new concept, with the only success being targeted antibody based therapeutics (including monoclonal and conjugated antibodies). Interest has surged in other classes of immunotherapeutics; these include Immune Checkpoint Inhibitors, therapeutic cancer vaccines and other whole cell based therapies.

Immune checkpoints are molecules that regulate (stimulate or inactivate) the immune cells. Yervoy (an anti CTLA-4 drug), the foremost drug to be launched in this domain, is currently being mirrored by various other drugs such as Opdivo, Keytruda (both anti PD-1 drugs) and many under clinical development. The market, with an opportunistic development pipeline, caters to the participation of various market players (big and small) over a common platform. With an ongoing rush to emerge as leaders in the evolving market, various stakeholders have collaborated to establish their foothold in a relatively short time period.

In addition to the marketed drugs (Yervoy, Opdivo and Keytruda), we expect a number of drugs currently in advanced stages of development (Tremelimumab, Elotuzumab, RG7446 and Avelumab) to achieve blockbuster status in the near future. The anticipated success of Immune Checkpoint Inhibitors shall prove to be a harbinger for emerging players and a strong impetus to the development pace of the other pharmaceutical giants.

SCOPE OF THE REPORT
The “Immune Checkpoint Inhibitors Market (2nd edition), 2015-2025” report provides a comprehensive analysis of the current market landscape and the future outlook of the growing pipeline of Immune Checkpoint Inhibitors. The immuno-oncology market encompasses a myriad of immune checkpoint targeting drugs which can be potentially exploited for a broad range of cancer indications. Specifically, CTLA-4 inhibitors were the pioneers in this segment. Yervoy, the flagship molecule from BMS, was the only immunotherapeutic commercially available until other classes recently stepped in. The recent approval of anti PD-1 drugs and emergence of anti PD-L1 drugs has provided a significant boost to the market.

In addition, there are several novel checkpoint inhibitors (e.g. IDO, LAG-3, CD70, OX40, CD40, GITR, TIM-3, CD137/4-1BB, KIR, TDO, VISTA, CS1, NKG2A, GARP, ICOS) which have recently gained ground and are expected to retain attention in the future.

One of the key objectives of the study is to review the opportunities laid by the robust, opportunistic and broad pipelines of the pharmaceutical firms. With three marketed drugs (Yervoy, Keytruda and Opdivo), the market is treading its way towards fulfilling the huge untapped promise. Amongst other elements, the report elaborates upon the following key areas:

The current state of the market with respect to key players, developmental stage of pipeline products (both clinical / pre-clinical) and indications targeted
Recent partnerships which have taken place over the last five years including product co-development, licensing and clinical trial collaborations
Combination therapies where Immune Checkpoint Inhibitors are being evaluated in combination with other anti-cancer agents/therapies
Various investments and grants received by the companies focused in this area
Competitive landscape and inherent threats to growth in the short and long term
Development and sales potential based on target consumer segments, likely adoption rate and expected pricing

The base year for the report is 2015. The report provides the market forecast for the period 2015-2025, respectively. The research, analysis and insights presented in this report include potential sales of several Immune Checkpoint Inhibitors; this analysis is backed by a deep understanding of key drivers behind the growth.

Owing to niche nature of the market, with most products in the pipeline, we have provided three market forecast scenarios to add robustness to our model. The conservative, base and optimistic scenarios represent three different tracks of industry evolution. All actual figures have been sourced and analyzed from publicly available information. The figures mentioned in this report are in USD, unless otherwise specified.

EXAMPLE HIGHLIGHTS
1. The industry is characterized by the presence of three marketed drugs and 34 drugs in clinical development for oncological indications. The marketed and clinical pipeline includes two CTLA-4, nine PD-1/ PD-L1 and 26 novel Immune Checkpoint Inhibitors. The dynamic pipeline also includes several molecules in preclinical / discovery stage; in our research, we identified about 70 such molecules.

2. BMS, with ten Immune Checkpoint Inhibitors (marketed / under development), is the leading player. Other pharmaceutical giants include AstraZeneca, Merck & Co, Pfizer, Merck KGaA, Roche, GSK, Novartis and Amgen.

3. Many start-ups, small companies and university spin-offs have also emerged in the past two years. Examples (in alphabetical order) include Agenus, Alligator Bioscience, Ambrx, AnaptysBio, arGEN-X, Bioceros, BioNovion, Cellerant Therapeutics, Checkpoint Therapeutics, Compugen, CureTech, Enumeral, Five Prime Therapeutics, Genmab, GITR, ImmuNext, IOmet Pharma, iTeos Therapeutics, Jounce Therapeutics, KAHR Medical, Multimeric Biotherapeutics, Nativis, Orega Biotech, Pelican Therapeutics, Pieris Pharmaceuticals, Prima BioMed, Redx Pharma, Sorrento Therapeutics, Tesaro, TG Therapeutics, Theravectys and ToleroTech.

4. Amongst the novel Immune Checkpoint Inhibitors, IDO inhibitors have gained maximum attention; this is followed by molecules targeting LAG-3, CD-70, OX-40 and CD-40. Although Elotuzumab is the only drug in late stage development, novel checkpoints have paved the way for smaller biotechnology firms to enter the immuno-oncology market.

5. Collaborations have helped the market reach its current growth trajectory. Specifically, clinical trial collaborations to evaluate Immune Checkpoint Inhibitors as combination therapies are very common; the period Jan 2014 - May 2015 saw over 40 such collaborations for a number of molecules.

6. We expect Immune Checkpoint Inhibitors to be a multi-billion dollar market over the coming decade; during the period 2015 - 2025, our forecast suggests that the market will witness an annualized growth rate of 27.7%.

RESEARCH METHODOLOGY
Most of the data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include
Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts’ views

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.


1. Preface
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. Executive Summary
3. Cancer Therapeutics and Immuno-Oncology
3.1. Chapter Overview
3.2. The Four Pillars of Cancer Therapy
3.3. Immunotherapy: Gaining A Strong Foothold
3.3.1. Activation and Suppression Immunotherapies
3.4. Immuno-Oncology (Cancer Immunotherapy)
3.5. Classification of Cancer Immunotherapies
3.5.1. By Mechanism of Action
3.5.2. By Product Class
3.5.2.1. Monoclonal Antibodies (mAbs)
3.5.2.2. Cytokines
3.5.2.3. Cell Based Therapies
3.5.2.4. Immune Checkpoint Inhibitors
4. Current Market Landscape
4.1. Scope and Observations
4.2. Common Targets for Immune Checkpoint Inhibitors
4.3. Three Approved Immune Checkpoint Inhibitors in Market
4.4. Immune Checkpoint Inhibitors: Clinical and Preclinical Pipeline
4.4.1. Immune Checkpoint Inhibitors: Distribution by Drug Developers
4.4.2. Immune Checkpoint Inhibitors: Distribution by Targets
4.4.3. Immune Checkpoint Inhibitors: Distribution by Highest Phase of Development
4.4.4. Immune Checkpoint Inhibitors: Distribution by Type of Molecule
4.5. Overall Future Outlook: Sales Forecast, 2015 - 2025
4.5.1. Scope and Forecast Methodology
4.5.2. Overall Market Size and Forecast
5. CTLA-4 Inhibitors: Key Molecules and Future Outlook
5.1. CTLA-4 Inhibitors: Mechanism of Action
5.2. Pioneers of Immune Checkpoint Inhibitors Market
5.3. CTLA-4 Inhibitors: Pipeline Analysis
5.3.1. CTLA-4 Inhibitors: Distribution by Highest Phase of Development
5.3.2. CTLA-4 Inhibitors: Distribution by Type of Molecule
5.4. Yervoy / Ipilimumab (Bristol Myers Squibb)
5.4.1. Introduction
5.4.2. History of Development
5.4.3. Dosage and Manufacturing
5.4.4. Treatment Cost and Reimbursement
5.4.5. Current Status of Development
5.4.6. Key Clinical Trial Results
5.4.7. Historical Sales
5.4.8. Patent Expiry
5.4.9. Collaborations
5.4.10. Target Patient Population
5.4.11. Yervoy/ Ipilimumab Sales Forecast, 2015 – 2025
5.5. Tremelimumab (MedImmune)
5.5.1. Introduction
5.5.2. History of Development
5.5.3. Current Status of Development
5.5.4. Key Clinical Trial Results
5.5.5. Collaborations
5.5.6. Target Patient Population
5.5.7. Tremelimumab Sales Forecast, 2015 – 2025
5.6. CTLA-4 Inhibitors: Roots Analysis’ Perspective
6. PD-1 and PD-L1 Inhibitors: Key Molecules and Future Outlook
6.1. PD-1/PD-L1 Inhibitors: Mechanism of Action
6.2. Two Recent Launches Have Strengthened the Market Sentiment
6.3. PD-1 / PD-L1 Inhibitors: Pipeline Analysis
6.3.1. PD-1 / PD-L1 Inhibitors: Landscape Analysis
6.3.2. PD-1 / PD-L1 Inhibitors: Distribution by Target
6.3.3. PD-1 / PD-L1 Inhibitors: Distribution by Highest Phase of Development
6.3.4. PD-1 / PD-L1 Inhibitors: Distribution by Type of Molecule
6.4. Opdivo/Nivolumab (Bristol Myers Squibb)
6.4.1. Introduction
6.4.2. History of Development
6.4.3. Dosage and Manufacturing
6.4.4. Treatment Cost and Reimbursement
6.4.5. Current Status of Development
6.4.6. Key Clinical Trial Results
6.4.6.1. Metastatic Melanoma (Single Agent)
6.4.6.2. NSCLC
6.4.6.3. Advanced Melanoma (Combination Therapy)
6.4.6.4. Hodgkin Lymphoma
6.4.6.5. RCC
6.4.6.6. Hepatocellular Carcinoma
6.4.7. Historical Sales
6.4.8. Patent Expiry
6.4.9. Collaborations
6.4.10. Target Patient Population
6.4.11. Opdivo /Nivolumab Sales Forecast, 2015 – 2025
6.5. Keytruda / Pembrolizumab (Merck)
6.5.1. Introduction
6.5.2. History of Development
6.5.3. Dosage and Manufacturing
6.5.4. Treatment Cost and Reimbursement
6.5.5. Current Status of Development
6.5.6. Key Clinical Trial Results
6.5.8.1. Advanced Melanoma
6.5.8.2. NSCLC
6.5.8.3. Advanced Solid Tumors
6.5.8.4. Hodgkin Lymphoma
6.5.8.5. Advanced Head and Neck Cancer
6.5.8.6. Advanced Bladder Cancer
6.5.8.7. Advanced Gastric Cancer
6.5.8.8. Metastatic Breast Cancer
6.5.7. Historical Sales
6.5.8. Patent Expiry
6.5.9. Collaborations
6.5.10. Target Patient Population
6.5.11. Keytruda / Pembrolizumab Sales Forecast, 2015 – 2025
6.6. MPDL3280A/RG7446 (Roche)
6.6.1. Introduction
6.6.2. History of Development
6.6.3. Current Status of Development
6.6.4. Key Clinical Trial Results
6.6.4.1. NSCLC
6.6.4.2. Metastatic Bladder Cancer
6.6.4.3. Metastatic Breast Cancer
6.6.4.4. Metastatic Renal Cell Carcinoma
6.6.5. Collaborations
6.6.6. Target Patient Population
6.6.7. MPDL3280A/RG7446 Sales Forecast, 2015 – 2025
6.7. MEDI4736 (MedImmune)
6.7.1. Introduction
6.7.2. Current Status of Development
6.7.3. Key Clinical Trial Results
6.7.4. Collaborations
6.7.5. Target Patient Population
6.7.6. MEDI4736 Sales Forecast, 2015 – 2025
6.8. Avelumab/MSB0010718C (Merck KGaA/Pfizer)
6.8.1. Introduction
6.8.2. Current Status of Development
6.8.3. Key Clinical Trial Results
6.8.4. Collaborations
6.8.5. Target Patient Population
6.8.6. Avelumab /MSB0010718C Sales Forecast, 2015-2025
6.9. Pidilizumab/ CT-011 (CureTech)
6.9.1. Introduction
6.9.2. Current Status of Development
6.9.3. Key Clinical Trial Results
6.9.3.1. Metastatic Melanoma
6.9.3.2. B-cell Lymphoma
6.9.3.3. Relapsed Follicular Lymphoma
6.9.4. Target Patient Population
6.9.5. Collaborations
6.10. PD -1 and PD- L1 Inhibitors: Roots Analysis’ Perspective
7. Novel Immune Checkpoint Inhibitors: Key Molecules and Future Outlook
7.1. Rush for the Novel Immune Checkpoints
7.2. Novel Immune Checkpoint Inhibitors: Pipeline Analysis
7.2.1. Novel Immune Checkpoint Inhibitors: Distribution by Target
7.2.2. Novel Immune Checkpoint Inhibitors: Distribution by Companies
7.2.3. Novel Immune Checkpoint Inhibitors: Distribution by Highest Phase of Development
7.2.4. Novel Immune Checkpoint Inhibitors: Distribution by Type of Molecule
7.3. Elotuzumab (Bristol Myers Squibb/AbbVie)
7.3.1. Introduction
7.3.2. Mechanism of Action
7.3.3. History of Development
7.3.4. Current Status of Development
7.3.5. Key Clinical Trial Results
7.3.6. Collaborations
7.3.7. Target Patient Population
7.3.8. Elotuzumab Sales Forecast, 2015– 2025
7.4. Epacadostat/INCB024360 (Incyte Corporation)
7.4.1. Introduction
7.4.2. Mechanism of Action
7.4.3. Manufacturing
7.4.4. Current Status of Development
7.4.5. Key Clinical Trial Results
7.4.6. Target Patient Population
7.4.7. Collaborations
7.5. Indoximod (NewLink Genetics)
7.5.1. Introduction
7.5.2. Mechanism of Action
7.5.3. Manufacturing
7.5.4. Current Status of Development
7.5.5. Key Clinical Trial Results
7.5.6. Patent Information
7.5.7. Target Patient Population
7.5.8. Collaborations
7.6. Lirilumab (Bristol Myers Squibb)
7.6.1. Introduction
7.6.2. Mechanism of Action
7.6.3. Current Status of Development
7.6.4. Key Clinical Trial Results
7.6.5. Target Patient Population
7.6.6. Collaborations
7.7. IPH2201 (Innate Pharma)
7.7.1. Introduction
7.7.2. Mechanism of Action
7.7.3. Current Status of Development
7.7.4. Key Clinical Trial Results
7.7.5. Target Patient Population
7.7.6. Collaborations
7.8. Novel Checkpoint Inhibitors: Roots Analysis’ Perspective
8. Immune Checkpoint Inhibitors as Combination Therapy
8.1. Introduction
8.2. Combination Therapy: History of Development
8.3. FDA approved Combination Therapies in Oncology
8.4. Combination Therapies: FDA Guidelines
8.4.1. Combinations of Previously Marketed Drugs or Biologics
8.4.2. Combinations of Previously Marketed Drugs or Biologics with New Molecular Entities
8.4.3. Combinations of New Molecular Entities with New Molecular Entities
8.5. Combination Therapies: Immune Checkpoint Inhibitors
8.5.1. Immune Checkpoint Inhibitors Clinical Studies: Distribution by Type of Therapy Evaluation
8.5.2. Immune Checkpoint Inhibitors Combination Therapy Clinical Studies
8.5.2.1. Distribution by Highest Phase of Development
8.5.2.2. Distribution by Status
8.5.2.3. Distribution by Type of Immune Checkpoint Inhibitor
8.5.2.4. Distribution by Type of Combination Class
8.6. Combination of Immune Checkpoint Inhibitors with Immune Checkpoint Inhibitors
8.7. Combination of Immune Checkpoint Inhibitors with Chemotherapy
8.8. Combination of Immune Checkpoint Inhibitors with Kinase Inhibitors
8.9. Combination of Immune Checkpoint Inhibitors with Angiogenesis Inhibitors
8.10. Combination of Immune Checkpoint Inhibitors with Cancer Vaccine
8.11. Combination of Immune Checkpoint Inhibitors with Cytokines
8.12. Combination of Immune Checkpoint Inhibitors with Radiotherapy
8.13. Combination of Immune Checkpoint Inhibitors with Surgery
8.14. Combination of Immune Checkpoint Inhibitors with Oncolytic Virus Immunotherapy
8.15. Combination of Immune Checkpoint Inhibitors with Cell Based Immunotherapy
8.16. Combination of Immune Checkpoint Inhibitors with Hormone Therapy
8.17. Combination of Immune Checkpoint Inhibitors with Other Drug Classes
9. Competition in Key Indication Areas
9.1. Chapter Overview
9.2. Competition in Melanoma Market
9.3. Competition in Malignant Mesothelioma Market
9.4. Competition in NSCLC Market
9.5. Competition in Multiple Myeloma Market
9.6. Competition in Ovarian Cancer Market
9.7. Competition in Bladder Cancer Market
9.8. Competition in Kidney Cancer Market
10. Deals and Partnerships
10.1. Chapter Overview
10.2. Collaborations Inked in Immune Checkpoint Inhibitors Market
10.2.1. Distribution by Type
10.2.2. Distribution by Year of Partnership
10.3. Large Pharmaceutical Companies Acquiring to Expand Pipelines
10.4. Co-development and/or Commercialization Agreements
10.5. Product Licensing Agreements
10.6. Clinical Trial Collaborations to Validate Combination Therapies
10.6.1. Clinical Trial Collaborations: Distribution by Target
10.6.2. BMS and Merck Have Been the Most Active In Forging Clinical Trial Collaborations
10.7. Contract Manufacturing Agreement
10.8. Research Collaborations
11. Venture Capital Support
11.1. Chapter Overview
11.2. Instances of Investments / Grants in Immune Checkpoint Inhibitors Market
11.3. Growing Venture Capitalist Interest
11.4. Distribution of the Funding Instances on the Basis of Type of Funding
11.5. Distribution by Total Amount of Investment in a Category
12. Company Profiles
12.1. Chapter Overview
12.2. Bristol Myer Squibb
12.2.1. Company Overview
12.2.2. Financial Performance
12.2.3. Immune Checkpoint Inhibitors Pipeline, 2015
12.2.4. Collaborations
12.3. Merck & Co.
12.3.1. Company Overview
12.3.2. Financial Performance
12.3.3. Immune Checkpoint Inhibitors Pipeline, 2015
12.3.4. Collaborations
12.4. AstraZeneca
12.4.1. Company Overview
12.4.2. Financial Performance
12.4.3. Immune Checkpoint Inhibitors Pipeline, 2015
12.4.4. Collaborations
12.5. Roche / Genentech
12.5.1. Company Overview
12.5.2. Financial Performance
12.5.3. Immune Checkpoint Inhibitors Pipeline, 2015
12.5.4. Collaborations
12.6. Pfizer
12.6.1. Company Overview
12.6.2. Financial Performance
12.6.3. Immune Checkpoint Inhibitors Pipeline, 2015
12.6.4. Collaborations
12.7. Incyte Corporation
12.7.1. Company Overview
12.7.2. Financial Performance
12.7.3. Immune Checkpoint Inhibitors Pipeline, 2015
12.7.4. Collaborations
12.8. NewLink Genetics
12.8.1. Company Overview
12.8.2. Financial Performance
12.8.3. Immune Checkpoint Inhibitors Pipeline, 2015
12.8.4. Collaborations
12.9. Innate Pharma
12.9.1. Company Overview
12.9.2. Financial Performance
12.9.3. Immune Checkpoint Inhibitors Pipeline, 2015
12.9.4. Collaborations
12.10. CureTech
12.10.1. Company Overview
12.10.2. Immune Checkpoint Inhibitors Pipeline, 2015
12.10.3. Collaborations
12.11. Celldex Therapeutics
12.11.1. Company Overview
12.11.2. Financial Performance
12.11.3. Immune Checkpoint Inhibitors Pipeline, 2015
12.11.4. Collaborations
12.12. arGEN-X
12.12.1. Company Overview
12.12.2. Technology Platforms
12.12.3. Financial Performance
12.12.4. Immune Checkpoint Inhibitors Pipeline, 2015
12.12.5. Collaborations
12.13. Seattle Genetics
12.13.1. Company Overview
12.13.2. Technology Platforms
12.13.3. Financial Performance
12.13.4. Immune Checkpoint Inhibitors Pipeline, 2015
12.13.5. Collaborations
12.14. MacroGenics
12.14.1. Company Overview
12.14.2. Technology Platforms
12.14.3. Financial Performance
12.14.4. Immune Checkpoint Inhibitors Pipeline, 2015
12.14.5. Collaborations
12.15. GlaxoSmithKline
12.15.1. Company Overview
12.15.2. Financial Performance
12.15.3. Immune Checkpoint Inhibitors Pipeline, 2015
12.15.4. Collaborations
12.16. GITR, Inc.
12.16.1. Company Overview
12.16.2. Immune Checkpoint Inhibitors Pipeline, 2015
12.16.3. Collaborations
12.17. Agenus
12.17.1. Company Overview
12.17.2. Financial Performance
12.17.3. Immune Checkpoint Inhibitors Pipeline, 2015
12.17.4. Collaborations
12.18. Compugen
12.18.1. Company Overview
12.18.2. Financial Performance
12.18.3. Immune Checkpoint Inhibitors Pipeline, 2015
12.18.4. Collaborations
12.19. Tesaro
12.19.1. Company Overview
12.19.2. Immune Checkpoint Inhibitors Pipeline, 2015
12.19.3. Collaborations
12.20. BioNovion
12.20.1. Company Overview
12.20.2. Technology Platform
12.20.3. Immune Checkpoint Inhibitors Pipeline, 2015
12.20.4. Collaborations
12.21. IOmet Pharma
12.21.1. Company Overview
12.21.2. Immune Checkpoint Inhibitors Pipeline, 2015
12.22. Enumeral Biomedical Holdings
12.22.1. Company Overview
12.22.2. Technology Platform
12.22.3. Immune Checkpoint Inhibitors Pipeline, 2015
12.22.4. Financial Performance
12.22.5. Collaborations
12.23 Immutep (PrimaBioMed)
12.23.1. Company Overview
12.23.2. Technology Platform
12.23.3. Immune Checkpoint Inhibitors Pipeline, 2015
12.23.4. Collaborations
13. Conclusion
13.1. Immune Checkpoint Inhibitors: A New Hope For Cancer Patients
13.2. Current Flag Bearers: PD-1 and PD-L1
13.3. Active Collaborations Likely To Be The Key To Future Success
13.4. With Several Blockbusters In The Pipeline, The Overall Opportunity Is Huge
13.5. Concluding Remarks
14. Interview Transcripts
15. Appendix: Tabulated Data
16. Appendix: List of Companies and Organizations
LIST OF FIGURES
Figure 3.1 The Four Pillars of Cancer Therapy
Figure 3.2 Passive and Active Cancer Immunotherapies
Figure 4.1 Immune Checkpoint Inhibitors: Distribution by Drug Developers
Figure 4.2 Immune Checkpoint Inhibitors: Distribution by Targets
Figure 4.3 Immune Checkpoint Inhibitors: Distribution by Highest Phase of Development
Figure 4.4 Immune Checkpoint Inhibitors: Distribution by Type of Molecule
Figure 4.5 Immune Checkpoint Inhibitors: Overall Sales Forecast, 2015 - 2025: Base Scenario (USD Million)
Figure 5.1 CTLA-4 Inhibitors: Distribution by Highest Phase of Development
Figure 5.2 CTLA-4 Inhibitors: Distribution by Type of Molecule
Figure 5.3 Yervoy / Ipilimumab Sales, 2011 - 2014 (USD Million)
Figure 5.4 Yervoy / Ipilimumab Sales Forecast, 2015 - 2025: Base Scenario (USD Million)
Figure 5.5 Tremelimumab Sales Forecast, 2015 - 2025: Base Scenario (USD Million)
Figure 5.6 CTLA-4 Inhibitors: Drivers and Restraints
Figure 6.1 PD-1 / PD-L1 Inhibitors: Distribution by Drug Developer
Figure 6.2 PD-1 / PD-L1 Inhibitors: Distribution by Target
Figure 6.3 PD-1 / PD-L1 Inhibitors: Distribution by Highest Phase of Development
Figure 6.4 PD-1 / PD-L1 Inhibitors: Distribution by Type of Molecule
Figure 6.5 Opdivo / Nivolumab Sales, 2014- Q1 2015 (USD Million)
Figure 6.6 Opdivo / Nivolumab Sales Forecast, 2015–2025: Base Scenario (USD Million)
Figure 6.7 Keytruda / Pembrolizumab Sales, 2014 - Q1 2015(USD Million)
Figure 6.8 Keytruda / Pembrolizumab Sales Forecast, 2015 - 2025: Base Scenario (USD Million)
Figure 6.9 MPDL3280A/RG7446 Sales Forecast, 2015 - 2025: Base Scenario (USD Million)
Figure 6.10 MEDI4736 Sales Forecast, 2015 - 2025: Base Scenario (USD Million)
Figure 6.11 Avelumab / MSB0010718C Sales Forecast, 2015 - 2025: Base Scenario (USD Million)
Figure 6.12 PD-1 and PD-L1 Inhibitors: Drivers and Restraints
Figure 7.1 Novel Immune Checkpoint Inhibitors Pipeline: Distribution by Target
Figure 7.2 Novel Immune Checkpoint Inhibitors Pipeline: Distribution by Companies
Figure 7.3 Novel Immune Checkpoint Inhibitors: Distribution by Highest Phase of Development
Figure 7.4 Novel Immune Checkpoint Inhibitors: Distribution by Type of Molecule
Figure 7.5 Elotuzumab Sales Forecast, 2015 - 2025: Base Scenario (USD Million)
Figure 7.6 Novel Immune Checkpoint Inhibitors: Drivers and Restraints
Figure 8.1 Immune Checkpoint Inhibitors Clinical Studies: Distribution by Type of Therapy Evaluation
Figure 8.2 Immune Checkpoint Inhibitors Combination Therapy Clinical Studies: Distribution by Highest Phase of Development
Figure 8.3 Immune Checkpoint Inhibitors Combination Therapy Clinical Studies: Distribution by Status
Figure 8.4 Immune Checkpoint Inhibitors Combination Therapy Clinical Studies: Distribution by Type of Immune Checkpoint Inhibitor
Figure 8.5 Immune Checkpoint Inhibitors Combination Therapy Clinical Studies: Distribution by Type of Combination Class
Figure 10.1 Collaborations Inked in Immune Checkpoint Inhibitors Market: Distribution by Type
Figure 10.2 Collaborations Inked in Immune Checkpoint Inhibitors Market: Distribution by Year of Partnership
Figure 10.3 Clinical Trial Collaborations: Distribution by Target
Figure 11.1 Immune Checkpoint Inhibitors Funding Instances: Cumulative Investments by Year, 2001–2015
Figure 11.2 Immune Checkpoint Inhibitors Funding Instances: Distribution by Categories
Figure 11.3 Immune Checkpoint Inhibitors Funding Instances: Distribution by Amount Invested in a Category (USD Million)
Figure 12.1 BMS Revenues, 2011 - Q1 2015 (USD Billion)
Figure 12.2 BMS Revenues: Distribution by Therapeutic Areas, 2013 – 2014 (USD Million)
Figure 12.3 Merck Revenues, 2009 - Q1 2015 (USD Million)
Figure 12.4 Merck Revenues: Distribution by Business Segment, 2014 (USD Billion)
Figure 12.5 AstraZeneca Revenues, 2009 - Q1 2015(USD Million)
Figure 12.6 AstraZeneca Revenues: Distribution by Therapeutic Areas, 2013 -2014(USD Million)
Figure 12.7 Roche Revenues, 2009-Q1 2015 (CHF Billion)
Figure 12.8 Roche Revenues: Distribution by Business Segments, 2012 - 2014 (CHF Billion)
Figure 12.9 Roche Pharmaceutical Revenues: Distribution by Therapeutic Areas, 2014 (CHF Billion)
Figure12.10 Pfizer Revenues, 2011 - Q1 2015 (USD Billion)
Figure 12.11 Pfizer Revenues: Distribution by Business Segments, 2014 (USD Million)
Figure 12.12 Pfizer Revenues: Distribution by Therapeutic Areas, 2013 - 2014, (USD ‘000)
Figure 12.13 Incyte Corporation Revenues, 2011 - Q1 2015 (USD Million)
Figure 12.14 NewLink Genetics Revenues, 2011 - Q1 2015 (USD Million)
Figure 12.15 Innate Pharma Revenues, 2011 - Q1 2015 (EUR Million)
Figure 12.16 Celldex Therapeutics Revenues, 2011 - Q1 2015 (USD Million)
Figure 12.17 Seattle Genetics Revenues, 2011 - Q1 2015 (USD Million)
Figure 12.18 MacroGenics Revenues, 2011 - Q1 2015 (USD Million)
Figure12.19 GSK Revenues, 2009 - Q1 2015 (GBP Billion)
Figure12.20 GSK Pharmaceutical and Vaccine Revenues: Distribution by Business Domains 2014, (GBP Billion)
Figure12.21 Compugen Revenues, 2012 - Q1 2015 (USD Million)
Figure 12.22 Enumeral Revenues, 2013 - Q1 2015 (USD ‘000)
Figure 13.1 Immune Checkpoint Inhibitors Market (USD Billion), 2015, 2020 and 2025
LIST OF TABLES
Table 3.1 FDA Approved Antibody Based Therapeutics for Cancer
Table 4.1 Co-Stimulatory Molecules as Target for Immune Checkpoint Inhibition
Table 4.2 Immune Checkpoint Inhibitors: Marketed and Clinical Pipeline, 2015
Table 4.3 Immune Checkpoint Inhibitors: Preclinical and Discovery Pipeline, 2015
Table 4.4 Immune Checkpoint Inhibitors: Current Development Phase and Expected Launch Year of Drugs
Table 5.1 Pipeline of CTLA-4 Inhibitors, 2015
Table 5.2 Yervoy / Ipilimumab: History of Development
Table 5.3 Yervoy / Ipilimumab: Dosage and Packaging
Table 5.4 Yervoy / Ipilimumab: Current Status of Development
Table 5.5 Tremelimumab: Current Status of Development
Table 6.1 Pipeline of PD-1 and PD-L1 Inhibitors, 2015
Table 6.2 PD-1 / PD-L1 Inhibitors: Landscape Analysis
Table 6.3 Opdivo/Nivolumab: Dosage and Packaging
Table 6.4 Opdivo/Nivolumab: Current Status of Development
Table 6.5 Keytruda / Pembrolizumab: Current Status of Development
Table 6.6 MPDL3280A / RG7446: Current Status of Development
Table 6.7 MEDI4736: Current Status of Development
Table 6.8 Avelumab / MSB0010718C: Current Status of Development
Table 6.9 Pidilizumab / CT-011: Current Status of Development
Table 6.10 Pidilizumab / CT-011: Investigator Sponsored Clinical Studies
Table 7.1 Pipeline of Novel Immune Checkpoint Inhibitors, 2015
Table 7.2 Elotuzumab: Current Status of Development
Table 7.3 Epacadostat / INCB024360: Current Status of Development
Table 7.4 Indoximod: Current Status of Development
Table 7.5 NewLink Genetics: Patent Portfolio Related to IDO Inhibitors
Table 7.6 Lirilumab: Current Status of Development
Table 8.1 FDA Approved Combination Therapies in Oncology, 2001-2015
Table 8.2 Combination of Immune Checkpoint Inhibitors with Immune Checkpoint Inhibitors
Table 8.3 Combination of Immune Checkpoint Inhibitors with Chemotherapy
Table 8.4 Combination of Immune Checkpoint Inhibitors with Kinase Inhibitors
Table 8.5 Combination of Immune Checkpoint Inhibitors with Chemotherapy
Table 8.6 Combination of Immune Checkpoint Inhibitors with Cancer Vaccine
Table 8.7 Combination of Immune Checkpoint Inhibitors with Cytokines
Table 8.8 Combination of Immune Checkpoint Inhibitors with Radiotherapy
Table 8.9 Combination of Immune Checkpoint Inhibitors with Surgery
Table 8.10 Combination of Immune Checkpoint Inhibitors with Oncolytic Virus Immunotherapy
Table 8.11 Combination of Immune Checkpoint Inhibitors with Cell Based Immunotherapy
Table 8.12 Combination of Immune Checkpoint Inhibitors with Hormone Therapy
Table 8.13 Combination of Immune Checkpoint Inhibitors with Other Drug Classes
Table 9.1 Comparison of Marketed Targeted Therapeutics for Melanoma
Table 9.2 Comparison of Marketed Targeted Therapeutics for Metastatic NSCLC
Table 9.3 Comparison of Marketed Therapeutics for Multiple Myeloma
Table 9.4 Comparison of Marketed Therapeutics for Renal Cell Carcinoma
Table 10.1 Immune Checkpoint Inhibitors Market: Acquisitions
Table 10.2 Immune Checkpoint Inhibitors Market: Co-Development and / or Commercialization Agreements
Table 10.3 Immune Checkpoint Inhibitors Market: Product Licensing Agreements
Table 10.4 Immune Checkpoint Inhibitors Market: Clinical Trial Collaborations
Table 10.5 Immune Checkpoint Inhibitors Market: Contract Manufacturing Agreements
Table 10.6 Immune Checkpoint Inhibitors Market: Research Collaborations
Table 11.1 List of Funding Rounds / Grants and Investors Involved
Table 12.1 BMS: Immune Checkpoint Inhibitors Pipeline, 2015
Table 12.2 BMS: Immune Checkpoint Inhibitors Partnerships
Table 12.3 Merck: Immune Checkpoint Inhibitors Pipeline, 2015
Table 12.4 Merck: Immune Checkpoint Inhibitors Partnerships
Table 12.5 AstraZeneca / MedImmune: Immune Checkpoint Inhibitors Pipeline, 2015
Table 12.6 AstraZeneca / MedImmune: Immune Checkpoint Inhibitors Partnerships
Table 12.7 Roche / Genentech: Immune Checkpoint Inhibitors Pipeline, 2015
Table 12.8 Roche / Genentech: Immune Checkpoint Inhibitors Partnerships
Table 12.9 Pfizer: Immune Checkpoint Inhibitors Pipeline, 2015
Table 12.10 Pfizer: Immune Checkpoint Inhibitors Partnerships
Table 12.11 Incyte Corporation: Immune Checkpoint Inhibitors Pipeline, 2015
Table 12.12 Incyte Corporation: Immune Checkpoint Inhibitors Partnerships
Table 12.13 NewLink Genetics: Immune Checkpoint Inhibitors Pipeline, 2015
Table 12.14 NewLink Genetics: Immune Checkpoint Inhibitors Partnerships
Table 12.15 Innate Pharma: Immune Checkpoint Inhibitors Pipeline, 2015
Table 12.16 Innate Pharma: Immune Checkpoint Inhibitors Partnerships
Table 12.17 CureTech: Immune Checkpoint Inhibitors Pipeline, 2015
Table 12.18 Celldex Therapeutics: Immune Checkpoint Inhibitors Pipeline, 2015
Table 12.19 Celldex Therapeutics: Immune Checkpoint Inhibitors Partnerships
Table 12.20 arGEN-X: Immune Checkpoint Inhibitors Pipeline, 2015
Table 12.21 arGEN-X: Immune Checkpoint Inhibitors Partnerships
Table 12.22 Seattle Genetics: Immune Checkpoint Inhibitors Pipeline, 2015
Table 12.23 MacroGenics: Immune Checkpoint Inhibitors Pipeline, 2015
Table 12.24 GSK: Immune Checkpoint Inhibitors Pipeline, 2015
Table 12.25 GITR: Immune Checkpoint Inhibitors Pipeline, 2015
Table 12.26 Agenus Immune Checkpoint Inhibitors Pipeline, 2015
Table 12.27 Agenus: Immune Checkpoint Inhibitors Partnerships
Table 12.28 Compugen Immune Checkpoint Inhibitors Pipeline, 2015
Table 12.29 Compugen: Immune Checkpoint Inhibitors Partnerships
Table 12.30 Tesaro Immune Checkpoint Inhibitors Pipeline, 2015
Table 12.31 Tesaro: Immune Checkpoint Inhibitors Partnerships
Table 12.32 BioNovion Immune Checkpoint Inhibitors Pipeline, 2015
Table 12.33 BioNovion: Immune Checkpoint Inhibitors Partnerships
Table 12.34 Immutep (Prima Biomed) Immune Checkpoint Inhibitors Pipeline, 2015
Table 15.1 Immune Checkpoint Inhibitors: Distribution by Drug Developers
Table 15.2 Immune Checkpoint Inhibitors: Distribution by Targets
Table 15.3 Immune Checkpoint Inhibitors: Distribution by Highest Phase of Development
Table 15.4 Immune Checkpoint Inhibitors: Distribution by Type of Molecule
Table 15.5 Immune Checkpoint Inhibitors: Overall Sales Forecast, 2015 - 2025: Conservative Scenario (USD Million)
Table 15.6 Immune Checkpoint Inhibitors: Overall Sales Forecast, 2015 - 2025: Base Scenario (USD Million)
Table 15.7 Immune Checkpoint Inhibitors: Overall Sales Forecast, 2015 - 2025: Optimistic Scenario (USD Million)
Table 15.8 CTLA-4 Inhibitors: Distribution by Highest Phase of Development
Table 15.9 CTLA-4 Inhibitors: Distribution by Type of Molecule
Table 15.10 Yervoy Sales, 2011 – 2014(USD Million)
Table 15.11 Yervoy / Ipilimumab Sales Forecast, 2015 - 2025: Conservative Scenario (USD Million)
Table 15.12 Yervoy / Ipilimumab Sales Forecast, 2015 - 2025: Base Scenario (USD Million)
Table 15.13 Yervoy / Ipilimumab Sales Forecast, 2015 - 2025: Optimistic Scenario (USD Million)
Table 15.14 Tremelimumab Sales Forecast, 2015 - 2025: Conservative Scenario (USD Million)
Table 15.15 Tremelimumab Sales Forecast, 2015 - 2025: Base Scenario (USD Million)
Table 15.16 Tremelimumab Sales Forecast, 2015 - 2025: Optimistic Scenario (USD Million)
Table 15.17 PD-1 / PD-L1 Inhibitors: Distribution by Drug Developer
Table 15.18 PD-1 / PD-L1Inhibitors: Distribution by Target
Table 15.19 PD-1 / PD-L1 Inhibitors: Distribution by Highest Phase of Development
Table 15.20 PD-1 / PD-L1Inhibitors: Distribution by Type of Molecule
Table 15.21 Opdivo / Nivolumab Sales, 2014- Q1 2015(USD Million)
Table 15.22 Opdivo / Nivolumab Sales Forecast, 2015 - 2025: Conservative Scenario (USD Million)
Table 15.23 Opdivo / Nivolumab Sales Forecast, 2015 - 2025: Base Scenario (USD Million)
Table 15.24 Opdivo / Nivolumab Sales Forecast, 2015 - 2025: Optimistic Scenario (USD Million)
Table 15.24 Keytruda / Pembrolizumab Sales, 2014-Q1 2015(USD Million)
Table 15.25 Keytruda /Pembrolizumab Forecast, 2015 - 2025: Conservative Scenario (USD Million)
Table 15.26 Keytruda /Pembrolizumab Sales Forecast, 2015 - 2025: Base Scenario (USD Million)
Table 15.27 Keytruda /Pembrolizumab Sales Forecast, 2015 - 2025: Optimistic Scenario (USD Million)
Table 15.28 MPDL3280A/RG7446 Sales Forecast, 2015 - 2025: Conservative Scenario (USD Million)
Table 15.29 MPDL3280A/RG7446 Sales Forecast, 2015 - 2025: Base Scenario (USD Million)
Table 15.30 MPDL3280A/RG7446 Sales Forecast, 2015 - 2025: Optimistic Scenario (USD Million)
Table 15.31 MEDI4736 Sales Forecast, 2015 - 2025: Conservative Scenario (USD Million)
Table 15.32 MEDI4736 Sales Forecast, 2015 - 2025: Base Scenario (USD Million)
Table 15.33 MEDI4736 Sales Forecast, 2015 - 2025: Optimistic Scenario (USD Million)
Table 15.34 Avelumab / MSB0010718C Sales Forecast, 2015 - 2025: Conservative Scenario (USD Million)
Table 15.35 Avelumab / MSB0010718C Sales Forecast, 2015 - 2025: Base Scenario (USD Million)
Table 15.36 Avelumab / MSB0010718C Sales Forecast, 2015 - 2025: Optimistic Scenario (USD Million)
Table 15.37 Novel Immune Checkpoint Inhibitors Pipeline: Distribution by Target
Table 15.38 Novel Immune Checkpoint Inhibitors Pipeline: Distribution by Companies
Table 15.39 Novel Immune Checkpoint Inhibitors: Distribution by Highest Phase of Development
Table 15.40 Novel Immune Checkpoint Inhibitors: Distribution by Type of Molecule
Table 15.41 Elotuzumab Sales Forecast, 2015 - 2025: Base Scenario (USD Million)
Table 15.42 Elotuzumab Sales Forecast, 2015 - 2025: Conservative Scenario (USD Million)
Table 15.43 Elotuzumab Sales Forecast, 2015 - 2025: Optimistic Scenario (USD Million)
Table 15.44 Immune Checkpoint Inhibitors Clinical Studies: Distribution by Type of Therapy Evaluation
Table 15.45 Immune Checkpoint Inhibitors Combination Therapy Clinical Studies: Distribution by Highest Phase of Development
Table 15.46 Immune Checkpoint Inhibitors Combination Therapy Clinical Studies: Distribution by Status of Development
Table 15.47 Immune Checkpoint Inhibitors Combination Therapy Clinical Studies: Distribution by Type of Immune Checkpoint Inhibitor
Table 15.48 Immune Checkpoint Inhibitors Combination Therapy Clinical Studies: Distribution by Type of Combination Class
Table 15.49 Collaborations Inked in Immune Checkpoint Inhibitors Market: Distribution by Type
Table 15.50 Collaborations Inked in Immune Checkpoint Inhibitors Market: Distribution by Year of Partnership
Table 15.51 Clinical Trial Collaborations: Distribution by Target
Table 15.52 Immune Checkpoint Inhibitors Funding Instances: Cumulative Investments by Year, 2001 - 2015
Table 15.53 Immune Checkpoint Inhibitors Funding Instances: Distribution by Categories
Table 15.54 Immune Checkpoint Inhibitors Funding Instances: Distribution by Amount Invested in a Category (USD Million)
Table 15.55 BMS Revenues, 2011 - Q1 2015 (USD Billion)
Table 15.56 BMS Revenues: Distribution by Therapeutic Areas, 2013 -2014(USD Million)
Table 15.57 Merck Revenues, 2009 - Q1 2015 (USD Million)
Table 15.58 Merck Revenues: Distribution by Business Segment, 2014 (USD Billion)
Table 15.59 AstraZeneca Revenues, 2009 - Q1’2015(USD Million)
Table 15.60 AstraZeneca Revenues: Distribution by Therapeutic Areas, 2013 -2014(USD Million)
Table 15.61 Roche Revenues, 2009 - Q120154 (CHF Billion)
Table 15.62 Roche Revenues: Distribution by Business Segments, 2012 - 2014 (CHF Billion)
Table 15.63 Roche Pharmaceutical Revenues: Distribution by Therapeutic Areas, 2014 (CHF Billion)
Table 15.64 Pfizer Revenues, 2011-Q1 2015 (USD Billion)
Table 15.65 Pfizer Revenues: Distribution by Business Segments, 2014 (USD Million)
Table 15.66 Pfizer Revenues: Distribution by Therapeutic Areas, 2013 - 2014, (USD ‘000)
Table 15.67 Incyte Corporation Revenues, 2011 - Q12015 (USD Million)
Table 15.68 NewLink Genetics Revenues, 2011 - Q1 2015(USD Million)
Table 15.69 Innate Pharma Revenues, 2011-Q1 2015(EUR Million)
Table 15.70 Celldex Therapeutics Revenues, 2011 - Q1 2015(USD Million)
Table 15.71 Seattle Genetics Revenues, 201 - Q1 2015(USD Million)
Table 15.72 MacroGenics Revenues, 2011 - Q1 2015(USD Million)
Table 15.73 GSK Revenues, 2009 - Q1 2015 (GBP Billion)
Table 15.74 GSK Pharmaceutical and Vaccine Revenues: Distribution by Business Domains 2014, (GBP Billion)
Table 15.75 Compugen Revenues, 2012 - Q1 2015 (USD Million)
Table 15.76 Enumeral Revenues, 2013 - Q1 2015 (USD ‘000)
Table 15.77 Immune Checkpoint Inhibitors Market (USD Billion), 2015, 2020 and 2025

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report